| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Rare Diseases |
Recent Updates
Recently added Catalysts
Rafael Holdings, Inc. Class B Common Stock$2.45
+0.11 (+4.67%)
F 13Pipeline Score Tools & Services · Clinical
Market Cap
65.55 M
EPS
-0.78
P/E Ratio
-1.61 $
Value Trade
74.03 K
SEC Financials
Q4 2025Dilution Risk
25%Revenue
240.00 K
R&D Expenses
7.48 M
Operating CF
-6.81 M
Total Assets
105.38 M
Total Liabilities
16.20 M
Equity
85.18 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
45.54 M
Monthly Burn
2.27 M
Runway
17.1 mo
Burn Trend
SEC Filing
Dec 12, 2025
Overview
Volume
48.04 K
52 Week Range
1.12 - 3.19
% held by Insiders
32.69 %
% held by Institutions
6.77 %
Enterprise Value
32.52 M
Total Shares
51.19 M
Short %
0.38 %
Float Shares
30.71 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rafael Holdings, Inc. Class B Common Stock
143Total events
3Upcoming
43Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 2
TBD
T1NDA Submission
Subscribe to view catalyst details
TBD
T2EU MAA Submission
Subscribe to view catalyst details
Event history 2
TBD
◆Topline ReadoutClinical Data
Subscribe to view catalyst details
TBD
▲Pre NDA MeetingFDA Meeting
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F13
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 9%
Micro Cap (rank 831 of 912)
Percentile RankRafael Holdings, Inc. Class B Common Stock has significant pipeline risk (13/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Trappsol Cyclo Fast TrackOrphanRare Pediatric | Niemann-Pick Disease Type C1 (NPC1) | Phase 3 | 2025-06-18 | Data on the investigational candidate Trappsol Cyclo indicates that it is well-tolerated and has a safety profile consistent with the previously completed phase 1 and 2 studies. Read More | Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data Phase Read More | |
Trappsol Cyclo Fast TrackOrphanRare Pediatric | Niemann-Pick Disease Type C1 (NPC1) | Phase 3 | 2025-06-18 | Data on the investigational candidate Trappsol Cyclo indicates that it is well-tolerated and has a safety profile consistent with the previously completed phase 1 and 2 studies. Read More | Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data Phase Read More | |
Trappsol Cyclo Fast TrackOrphanRare Pediatric | Niemann-Pick Disease Type C1 (NPC1) | Phase 3 | 2025-06-18 | Data on the investigational candidate Trappsol Cyclo indicates that it is well-tolerated and has a safety profile consistent with the previously completed phase 1 and 2 studies. Read More | Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data Phase Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RFL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RFL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-RFL
Jul 9, 2026▼ -7.3%on this news
Ronald McDonald House Westside LA Receives $1 Million Gift From The Rafael and Sharyl Mendez Family Foundation
Ronald McDonald House Westside LA has received a generous $1 million donation from The Rafael and Sharyl Mendez Family Foundation. This funding will aid in establishing a new Ronald McDonald House on Hilgard Avenue in Westwood Village. The facility aims to provide essential support for families with hospitalized children, helping them stay close during difficult times.
Read more →-RFL
Jun 11, 2026▲ +19.1%on this news· ran to +43% by day 3
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
Rafael Holdings reported its financial results for Q3 FY 2026, highlighting the completion of its pivotal Phase 3 TransportNPC trial. The company anticipates submitting its New Drug Application in the latter half of 2026, aiming to address the unmet needs of Niemann-Pick Disease Type C1. Despite a net loss of $4.2 million, the company sees potential for long-term shareholder value.
Read more →-RFL
Jun 10, 2026▼ -7.8%on this newsshared move
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Rafael Holdings has completed the last patient visit in its pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™ aimed at treating Niemann-Pick Disease Type C. The study involved 94 patients across 27 sites globally. Topline results are expected in the second half of 2026, with the company planning to submit an NDA following a pre-NDA meeting with the FDA.
Read more →-RFL
Apr 22, 2026Rafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease" License of the MIT patent strengthens Rafael's intellectual property around
Rafael Holdings, Inc. has secured an exclusive licensing agreement with MIT for a patent related to cyclodextrins aimed at improving myelination in ApoE4 positive Alzheimer's disease patients. This licensing strengthens Rafael's intellectual property portfolio regarding its lead candidate, Trappsol Cyclo, which could significantly impact the treatment landscape for a substantial patient population. Preclinical data suggests that Trappsol Cyclo may enhance cholesterol delivery within the central nervous system and improve cognitive functions. The agreement marks a pivotal step for Rafael Holdings in its clinical development efforts.
Read more →-RFL
Mar 16, 2026Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results NEWARK, NJ
Rafael Holdings, Inc. has reported its financial results for the second quarter of fiscal 2026, which showed an increased net loss largely attributed to the consolidation of Cyclo Therapeutics' expenses post-acquisition. Despite the financial challenges, the company is optimistic about its pivotal Phase 3 study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1, with positive recommendations from the Data Monitoring Committee. The company anticipates providing preliminary results in the upcoming third quarter, aiming to advance treatment options for this rare genetic disorder.
Read more →-RFL
Dec 11, 2025Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results NEWARK, NJ
Rafael Holdings, Inc. reported its financial results for the first quarter of fiscal year 2026, ending October 31, showing a net loss of $9.8 million. Despite the increased losses largely due to consolidation costs from the acquisition of Cyclo Therapeutics, the company expressed satisfaction with the progress of their Phase 3 TransportNPC study for Trappsol Cyclo. The Data Monitoring Committee has advised continuing the study based on positive safety and efficacy reviews, offering hope for patients with Niemann-Pick Disease Type C1.
Read more →-RFL
Oct 29, 2025Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results Cyclo Therapeutics' TransportNPC Phase 3 clinical trial for Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1, a rare and
Rafael Holdings has reported its financial results for the fourth quarter and full fiscal year 2025. The company highlighted ongoing progress in its pivotal Phase 3 clinical trial for Trappsol Cyclo, aimed at treating Niemann-Pick Disease Type C1. Despite achieving a successful rights offering, Rafael Holdings faced an increase in net loss due to consolidated expenses following recent acquisitions. Total cash and cash equivalents reported as of July 31, 2025, were $52.8 million.
Read more →-RFL
Oct 28, 2025Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors NEWARK, NJ
Rafael Holdings announced the passing of Lead Independent Director Stephen Greenberg and appointed Alan Grayson to its Board of Directors. Grayson will contribute his extensive legal and government experience, while existing board member Markus Sieger will serve as the new Lead Independent Director. The company acknowledges Greenberg's contributions, marking a significant change in its leadership structure. This governance transition might impact stakeholders as the company continues its strategic directions.
Read more →-RFL
Oct 10, 2025NASDAQ: RFL October 2025 | Investor Presentation Forward - Looking Statements Some of the information in this presentation relates to future events or future business and financial performance . Such statements constitut
Rafael Holdings, Inc. has provided an investor presentation detailing forward-looking statements primarily surrounding its lead product, Trappsol Cyclo, which is currently in Phase 3 trials for treating Niemann-Pick Disease Type C. The presentation outlines significant investment highlights, including a strong market potential, upcoming regulatory submissions, and positive interim analysis recommendations. Nevertheless, the company faces substantial risks, including dependency on the drug's regulatory approval and potential challenges in clinical trial outcomes. Overall, Rafael Holdings aims to deliver innovative therapies for patients with unmet medical needs.
Read more →-RFL
Jul 14, 2025▲ +6.3%on this news
FOURTH AMENDED AND RESTATED BY-LAWS OF RAFAEL HOLDINGS, INC. (hereinafter called the "Corporation") Effective as of
Rafael Holdings, Inc. has made amendments to its by-laws, effective July 14, 2025. The revisions include details regarding the corporation's registered office location, meeting protocols for stockholders, quorum requirements, and the process for consents without a meeting. These updates aim to clarify the governance structure and enhance corporate operations in compliance with legal requirements. The new by-laws address various administrative processes concerning stockholder meetings and voting procedures.
Read more →-RFL
Jun 18, 2025▼ -19.1%on this news
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data Phase
Rafael Holdings announced that the Phase 3 TransportNPC study for the treatment of Niemann-Pick Disease Type C1 (NPC1) will continue following a favorable independent review of interim data. The Data Monitoring Committee assessed the investigational drug Trappsol Cyclo's safety and efficacy data and recommended its progression to 96 weeks. Additionally, the FDA has accepted the study's statistical analysis plan, aiding Rafael's development goals. The company recently bolstered its financial position with a $25 million rights offering to support the drug's clinical evaluations.
Read more →-RFL
Jun 11, 2025▼ -27.7%on this news
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results Cyclo Therapeutics' TransportNPC Phase 3 clinical trial for Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic d
Rafael Holdings announced its third quarter fiscal 2025 financial results, reporting a net loss of $4.8 million, down from a previous loss of $32.4 million. The company is optimistic about the upcoming topline data from the interim analysis of the Phase 3 TransportNPC clinical trial for its product Trappsol Cyclo, which aims to treat Niemann-Pick Disease Type C1. Rafael's financial position has been bolstered by the recent completion of a $25 million rights offering. The increase in research and development expenses is attributed to the recent merger with Cyclo Therapeutics.
Read more →-RFL
Jun 4, 2025▲ +12.7%on this news· ran to +58% by day 3
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering NEWARK, NJ
Rafael Holdings, Inc. has announced the successful closing of its $25 million rights offering, resulting in subscriptions for over 3.1 million shares of Class B common stock. CEO Howard Jonas plans to backstop the offering to ensure all shares are subscribed. The proceeds from the offering will support the company's regulatory efforts and potential launch of Trappsol Cyclo, pending positive results from ongoing clinical trials for Niemann-Pick Disease Type C1. The total net proceeds expected from both the rights offering and backstop are approximately $24.9 million.
Read more →-RFL
May 20, 2025Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Deve
Rafael Holdings, Inc. announced an update regarding the subscription rights related to its public warrants. The update is linked to a previously announced $25 million rights offering intended to support the continued development of Trappsol Cyclo. Each subscription right allows shareholders to purchase shares of Class B common stock at a price of $1.28 per share. The rights offering is non-transferable and is set to expire on May 29, 2025, with conditions that may allow for termination prior to expiration. Additionally, the Executive Chairman has committed to purchase any unsold shares in the offering.
Read more →-RFL
May 6, 2025▼ -5.6%on this news
STANDBY PURCHASE AGREEMENT This STANDBY PURCHASE AGREEMENT (this " Agreement ") is made and entered into on
Rafael Holdings, Inc. has entered into a Standby Purchase Agreement with Howard S. Jonas to facilitate a Rights Offering aimed at raising $25 million. Under the agreement, holders of Class A and Class B Common Stock will gain Subscription Rights to purchase additional shares of Class B Common Stock at a price of $1.28 per share. The Standby Purchaser is committed to buying any shares that remain unsubscribed after the offering closes. This arrangement underscores the company's focus on securing necessary funding through shareholder engagement.
Read more →-RFL
May 5, 2025▼ -7.1%on this newsshared move
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol Cyclo NEWA
Rafael Holdings, Inc. announced a $25 million rights offering to support the development and potential launch of Trappsol Cyclo, targeting Niemann-Pick Disease Type C1. Eligible holders of Class A and B common stock as of May 9, 2025, can participate in the offering happening from May 13 to May 29, 2025. Howard Jonas, the company's Executive Chairman, will enter a Standby Purchase Agreement to acquire any unsubscribed shares, bolstering investor confidence in the initiative. This offering aids the advancement of Rafael's clinical pipeline.
Read more →-RFL
Apr 29, 2025Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol Cyclo NEWARK, NJ
Rafael Holdings, Inc. has announced a proposed $25 million rights offering intended to bolster its commitment to developing and potentially launching Trappsol Cyclo for Niemann-Pick Disease Type C1. The offering will allow existing stockholders the chance to purchase additional shares at a specific price and is contingent upon positive interim results from a clinical trial. Howard Jonas, the Company’s Executive Chairman, will act as a standby purchaser for any unsubscribed shares, enhancing financial assurance. Participation is restricted to holders of record as of May 9, 2025, with specific conditions attached to the offering.
Read more →-RFL
Apr 24, 2025Rafael Holdings Strengthens its Focus on the Development of Trappsol Cyclo and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role Cyclo Therapeutics' TransportNPC Phase 3 clinical trial f
Rafael Holdings has announced a strategic focus on the development of Trappsol Cyclo, a treatment for Niemann-Pick Disease Type C1, following its merger with Cyclo Therapeutics. CEO Bill Conkling will step down to assume an advisory role, with Howard Jonas taking over as CEO. The company is poised for the mid-2025 results from the interim analysis of the TransportNPC Phase 3 clinical trial, which could have significant implications for its product pipeline. Overall, the transition in leadership and upcoming trial results are pivotal for Rafael's future.
Read more →-RFL
Mar 26, 2025Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals Cyclo Therapeutics' TransportNPC Phase 3 clinical trial for Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1, a rar
Rafael Holdings has successfully completed its merger with Cyclo Therapeutics following approval from shareholders of both companies. This merger positions Rafael to advance its lead clinical asset, Trappsol Cyclo, which is currently undergoing a Phase 3 trial for the treatment of Niemann-Pick Disease Type C1. With the trial fully enrolled, interim results are anticipated in mid-2025. Both companies express optimism about their combined efforts to address this rare and serious condition.
Read more →-RFL
Mar 13, 2025Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its eff
Rafael Holdings has announced its financial results for the second quarter of fiscal 2025, highlighting a planned merger with Cyclo Therapeutics expected to close in Q3 pending shareholder approval. The company reported a net loss of $4.6 million for the quarter, compared to a net income of $6 million in the previous year. Despite these losses, there is optimism surrounding the ongoing Phase 3 clinical trial of Trappsol Cyclo for treating Niemann-Pick Disease, with topline data anticipated in mid-2025. Rafael Holdings aims to focus on this lead clinical program post-merger.
Read more →-RFL
Dec 11, 2024Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo's lead clinical program Trappsol Cyclo
Rafael Holdings, Inc. has reported its financial results for the first quarter of fiscal 2025, with a focus on the proposed merger with Cyclo Therapeutics. The merger is anticipated to proceed to a shareholder vote in early 2025, after which the company will prioritize its lead clinical program, Trappsol Cyclo. The Phase 3 study for Trappsol Cyclo has been fully enrolled, targeting Niemann-Pick Disease Type C1, with interim analysis results expected in mid-2025. Despite a reported increase in net losses compared to the previous year, the leadership remains optimistic about the drug's market potential.
Read more →-RFL
Nov 6, 2024Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which add
Rafael Holdings, Inc. reported its financial results for the fourth quarter and full fiscal year 2024, highlighting a proposed merger with Cyclo Therapeutics. The agreement aligns with Rafael's strategy to focus on clinical-stage assets targeting high unmet medical needs. While the company expressed optimism about Cyclo's ongoing Phase 3 trial for Trappsol Cyclo, it also reported significant financial losses for the year. The firm ended the fiscal year with $65.9 million in cash and marketable securities, but faces challenges due to increased expenses and prior losses.
Read more →-RFL
Aug 22, 2024Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement Cyclo Therapeutics' TransportNPC Phase 3 clinical trial for Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1, a rare and fat
Rafael Holdings and Cyclo Therapeutics have announced a definitive merger agreement to focus on developing Trappsol Cyclo for Niemann-Pick Disease Type C1. The TransportNPC Phase 3 clinical trial has been fully enrolled, with interim results expected by mid-2025. Rafael intends to finance the trial up to its interim analysis, consolidating resources for clinical innovations. Both companies' leadership expressed optimism about the partnership and its potential to deliver vital treatments for patients with high unmet medical needs.
Read more →-RFL
Jun 14, 2024Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive up
Rafael Holdings, Inc. reported financial results for the third quarter of fiscal 2024, highlighting a focus on advancing its investment portfolio and generating shareholder value. The company noted the positive progress of Cyclo Therapeutics in its treatment for Niemann-Pick Disease and the revenue generation from Day Three Labs. However, Rafael Holdings recorded a significant net loss driven by high research and development expenses. Total investments and adjustments in their financial strategies reflect ongoing changes in the company's operational focus.
Read more →-RFL
Mar 13, 2024Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments Incre
Rafael Holdings, Inc. reported its financial results for the second quarter of fiscal 2024, showing a net income of $5.9 million compared to a net loss from the previous year. The company has increased its ownership in Day Three Labs to a majority interest and announced the appointment of Dr. John Goldberg as the new Chief Medical Officer. Positive momentum is noted regarding Cyclo Therapeutics' clinical trial for Niemann-Pick Disease. However, there are losses associated with new investments and an increase in operational costs.
Read more →-RFL
Dec 14, 2023Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments NE
Rafael Holdings, Inc. reported its financial results for the first quarter of fiscal 2024, noting a net loss of $3.8 million, which is an improvement from the prior year’s $5.2 million loss. With cash and investments of $72.1 million, the company plans to focus on advancing its existing portfolio, as well as seeking new strategic investment opportunities. Key investments include support for Cyclo Therapeutics' Phase 3 trial and innovations in cannabis offerings through Day Three Laboratories. The report indicates operational losses remain despite progress in managing costs and strategic investments.
Read more →-RFL
Oct 30, 2023▲ +11%on this news
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportuni
Rafael Holdings, Inc. reported its financial results for the fourth quarter and full year of fiscal 2023, noting a significant reduction in net loss compared to the previous year. The company curbed expenses and sold its principal real estate holding for $33 million, enhancing its liquidity. Strategic investments in Cyclo Therapeutics and Day Three Laboratories are aimed at generating future value for shareholders. However, the company continues to incur losses from operations, raising concerns about sustainability amidst ongoing global market challenges.
Read more →-RFL
Jun 13, 2023▲ +7.3%on this news
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update Since the end of the third quarter, we made an initial $2.1 million investment in Cyclo Therapeutics, Inc. (Nasdaq: CYTH) a
Rafael Holdings, Inc. reported its financial results for the third quarter of fiscal 2023, showing an initial investment of $2.1 million in Cyclo Therapeutics, with plans for an additional $5 million. The company has seen a reduction in net losses compared to the previous year's period due to cost management and a strategic focus on valuable investments. Nonetheless, the net loss remains a point of concern as the company navigates its investments and expenditures.
Read more →-RFL
Apr 4, 2023▲ +17.7%on this news
Rafael Holdings Announces up to $5 Million Share Repurchase Program Announces expanded search for strategic opportunities beyond biopharma NEWARK, NJ
Rafael Holdings, Inc. has authorized a share repurchase program of up to $5 million for its Class B common stock, demonstrating confidence in its business strategy and financial position. CEO Bill Conkling stated that this move aims to enhance long-term shareholder value while the company explores strategic investment opportunities beyond the biopharmaceutical sector. The share repurchases will depend on market conditions and other considerations, reflecting a cautious but optimistic approach to capital deployment.
Read more →-RFL
Mar 14, 2023Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results NEWARK, NJ
Rafael Holdings, Inc. reported its financial results for the second quarter of fiscal 2023, highlighting a net loss of $3.3 million, an increase from $2.1 million in the same period last year. The company's research and development expenses fell to $2.2 million, attributed to the winding down of early-stage programs at the Barer Institute. CEO Bill Conkling noted the company's strong balance sheet and potential for strategic development opportunities, despite a cumulative net loss of $8.5 million in the first half of the year. Overall, the results reflect ongoing financial challenges alongside some positive operational adjustments.
Read more →-RFL
Dec 13, 2022Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results NEWARK, NJ
Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results NEWARK, NJ - December 13, 2022 (GLOBE NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022. "We are pleased
Read more →-RFL
Nov 15, 2022▲ +6.5%on this news
Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities NEWARK, NJ
Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities NEWARK, NJ - November 15, 2022 (GLOBE NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL) today announced its decision to curtail its early-stage development efforts
Read more →-RFL
Oct 31, 2022Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results NEWARK, NJ
Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results NEWARK, NJ - October 31, 2022 (GLOBE NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL), a holding company with interests in clinical and early-stage pharmaceutical companies, today reported its financial results
Read more →-RFL
Jun 14, 2022Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results NEWARK, NJ
Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results NEWARK, NJ - June 14, 2022 (GLOBE NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for the three and
Read more →-RFL
Mar 17, 2022Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results NEWARK, NJ
Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results NEWARK, NJ - March 17, 2022 (GLOBE NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for the three an
Read more →-RFL
Jan 21, 2022William "Bill" Conkling to assume the role of Chief Executive Officer as of
William "Bill" Conkling to assume the role of Chief Executive Officer as of February 1, 2022 NEWARK, NJ - January 21, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), a company focused on discovering and developing novel cancer and immune metabolism therapeuties th
Read more →-RFL
Dec 15, 2021Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating Results NEWARK, NJ
Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating Results NEWARK, NJ - December 15, 2021 (GLOBE NEWSWIRE) - Rafael Holdings, Inc., (NYSE: RFL), an early-stage cancer and immune metabolism therapeutics company, today reported its financial results for th
Read more →-RFL
Nov 22, 2021▼ -7.4%on this news
Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus - Ameet Mallik to Transition CEO Role to Chairman, Howard Jonas, and Will Remain a Highly Engaged Member of the Company's Board of Director
Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus - Ameet Mallik to Transition CEO Role to Chairman, Howard Jonas, and Will Remain a Highly Engaged Member of the Company's Board of Directors and Chair Newly Established Transition Committee - - Patrick Fa
Read more →-RFL
Oct 28, 2021▼ -73.2%on this news
Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613 (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia Phase 3
Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613 (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not M
Read more →-RFL
Oct 18, 2021Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business Update We expect Rafael Pharmaceuticals to report top line data from its AVENGER 500 Phase 3 registra
Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business Update expect Rafael Pharmaceuticals to report top line data from its AVENGER 500 Phase 3 registrational clinical trial in metastatic pancreatic cancer this calendar
Read more →-RFL
Sep 14, 2021Rafael Holdings Appoints Patrick Fabbio as Chief Financial Officer NEWARK, NJ
Holdings Appoints Patrick Fabbio as Chief Financial Officer NEWARK, NJ - September 14, 2021: Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pha
Read more →-RFL
Aug 10, 2021Harnessing the Power of Cancer Metabolism to Develop Innovative Therapeutics that Improve and Extend the Lives of Patients "To Save A Life Is To Save A Universe" August 2021 2 Copyright @ 2021. Rafael Holdings, Inc. Rafa
1 Harnessing the Power of Cancer Metabolism to Develop Innovative Therapeutics that Improve and Extend the Lives of Patients "To Save A Life Is To Save A Universe" August 2021 2 Copyright @ 2021. Rafael Holdings, Inc. Rafael Pharmaceuticals, Inc. Safe Harbor Statement This prese
Read more →-RFL
Jul 14, 2021Harnessing the Power of Cancer Metabolism to Develop Innovative Therapeutics that Improve and Extend the Lives of Patients "To Save A Life Is To Save A Universe" July 2021 Copyright @ 2021. Rafael Holdings, Inc. Rafael P
1 Harnessing the Power of Cancer Metabolism to Develop Innovative Therapeutics that Improve and Extend the Lives of Patients "To Save A Life Is To Save A Universe" July 2021 Copyright @ 2021. Rafael Holdings, Inc. Rafael Pharmaceuticals, Inc . 2 Copyright @ 2021. Rafael Holdings
Read more →-RFL
Jun 21, 2021Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology Company Rafael Pharmaceuticals' lead asset, CPI-613 (devimistat), is in Phase 3 clinical trials in pan
Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology Company Rafael Pharmaceuticals' lead asset, CPI-613 (devimistat), is in Phase 3 clinical trials in pancreatic cancer and relapsed or refractory acute myeloid l
Read more →-RFL
Jun 14, 2021Rafael Holdings Reports Third Quarter Fiscal Year 2021 Results NEWARK, NJ
Rafael Holdings Reports Third Quarter Fiscal NEWARK, NJ - June 14, 2021: Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.0 million and a loss per share of $0.15 for the third quarter of its 2021 fiscal year, the three months ended Q3 FY 2021 Operations and Consolida
Read more →-RFL
Mar 17, 2021Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results NEWARK, NJ
Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results NEWARK, NJ - March 17, 2021: Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.0 million and a loss per share of $0.50 for the second quarter of its 2021 fiscal year, the three months ended January 31, 2
Read more →-RFL
Mar 11, 2021Rafael Holdings Enhances Senior Management Team with Additions of Ameet Mallik, CEO and William Conkling, CCO Leadership Team Will Build on Pharma Investments NEWARK, NJ
Holdings Enhances Senior Management Team with Additions Mallik, CEO and William Conkling, CCO Leadership Team Will Build on Pharma NEWARK, NJ - March 11, 2021: Rafael Holdings, Inc., (NYSE: RFL), today announced that its Board of Directors has recruited Ameet Mallik to become
Read more →-RFL
Dec 15, 2020Rafael Holdings Reports First Quarter Fiscal Year 2021 Results NEWARK, NJ
Rafael Holdings Reports First Quarter Fiscal Year 2021 Results NEWARK, NJ - December 15, 2020: Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.1 million and a loss per share of $0.09 for the first quarter of its 2021 fiscal year, the three months ended October 31,
Read more →-RFL
Oct 29, 2020Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2020 Results NEWARK, NJ
Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2020 Results NEWARK, NJ - October 29, 2020: Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $4.9 million and a loss per share of $0.66 for the fiscal year ended July 31, 2020. Fourth quarter revenue was $1.2
Read more →-RFL
Jun 9, 2020Rafael Holdings Reports Third Quarter Fiscal Year 2020 Results NEWARK, NJ
Rafael Holdings Reports Third Quarter Fiscal Year 2020 Results NEWARK, NJ - June 9, 2020: Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.2 million and a loss per share of $0.14 for the fiscal quarter ended April 30, 2020. Q3 FY 2020 Consolidated Highlights Rafael
Read more →-RFL
Mar 5, 2020Rafael Holdings Reports Second Quarter Fiscal Year 2020 Results NEWARK, NJ
Rafael Holdings Reports Second Quarter Fiscal Year 2020 Results NEWARK, NJ - March 5, 2020: Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.2 million and a loss per diluted share of $0.08 for the fiscal quarter ended January 31, 2020. Recent Rafael Holdings Highlig
Read more →-RFL
Dec 9, 2019Rafael Holdings Reports First Quarter Fiscal Year 2020 Results Highlights Developments in Key Holdings Including Rafael Pharmaceuticals NEWARK, NJ
Rafael Holdings Reports First Quarter Fiscal Year 2020 Results Highlights Developments in Key Holdings Including Rafael Pharmaceuticals NEWARK, NJ - December 9, 2019: Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.2 million and a loss per share of $0.10 for the f
Read more →-RFL
Nov 18, 2019Rafael Holdings to Begin Trading on
Rafael Holdings to Begin Trading on NEWARK, NJ - November 18, 2019: Rafael Holdings, Inc., (NYSE American: RFL), announced today that it has been approved for listing on the New York Stock Exchange (NYSE). The Company anticipates that its Class B common stock will begin tradi
Read more →-RFL
Oct 4, 2019Holdings Reports Fourth Quarter and Full Fiscal Year 2019 Results
Holdings Reports Fourth Quarter and Full Fiscal Year 2019 Results NJ - October 3, 2019: Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $4.9 million and a loss per share of $0.35 for the fiscal year ended July 31, 2019. Fourth quarter revenue was $1.4 million a
Read more →-RFL
Jun 5, 2019Rafael Holdings Reports Third Quarter
Rafael Holdings Reports Third Quarter Fiscal Year 2019 Results NEWARK, NJ - June 5, 2019: Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $1.4 million and a loss per share of $0.07 for the third quarter of its 2019 fiscal year, the three months ended April 30
Read more →-RFL
Mar 12, 2019Rafael Holdings Reports Second Quarter Fiscal Year 2019 Results NEWARK, NJ
Rafael Holdings Reports Second Quarter Fiscal Year 2019 Results NEWARK, NJ - March 12, 2019: Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $1.0 million and a loss per share of $0.08 for the second quarter of its 2019 fiscal year, the three months ended Janu
Read more →-RFL
Jan 23, 2019Rafael Holdings Acquires Majority Stake in Rafael Pharma Rafael Pharma will utilize the investment to further advance the clinical development of devimistat (CPI-613 ) NEWARK, NJ
Rafael Holdings Acquires Majority Stake Rafael Pharma will utilize the investment to further advance the clinical development of devimistat (CPI-613 ) NEWARK, NJ - January 23, 2019: Rafael Holdings, Inc. (NYSE American: RFL) today announced that it has purchased a majority st
Read more →-RFL
Dec 10, 2018Rafael Holdings Reports First Quarter
Rafael Holdings Reports First Quarter Fiscal Year 2019 Results NEWARK, NJ - December 10, 2018: Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $1.1 million and a loss per share of $0.04 for the first quarter of its 2019 fiscal year, the three months ended Oct
Read more →-RFL
Dec 6, 2018December 6, 2018 LD Micro 2018 Conference
December 6, 2018 LD Micro 2018 Conference 2 This presentation contains forward - looking statements. Statements that are not historical facts are forward - looking statements and such forward - looking statements are statements made pursuant to the Safe Harbor Provisions of the
Read more →-RFL
Oct 15, 2018Holdings Reports Fourth Quarter and Full Fiscal Year 2018 Results
Holdings Reports Fourth Quarter and Full Fiscal Year 2018 Results NJ - October 15, 2018: Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $1.2 million and a loss per share of $0.05 for the fourth quarter of its 2018 fiscal year. For the full fiscal year 2018, re
Read more →-RFL
Sep 7, 2018Holdings Increases Stake in Rafael Pharma
Holdings Increases Stake in Rafael Pharma will provide Rafael Pharma with funding toward clinical trials of CPI-613 in both pancreatic cancer and acute myeloid leukemia NJ - September 7, 2018: Rafael Holdings, Inc. (NYSE American: RFL) today announced that, through a subsidiar
Read more →-RFL
Jun 11, 2018Holdings Reports Third Quarter Fiscal Year 2018 Results
Holdings Reports Third Quarter Fiscal Year 2018 Results NJ - June 11, 2018: Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $1.1 million and a loss per share of $0.04 for the third quarter of its 2018 fiscal year. are for 3Q FY2018 compared to 3Q FY2017) Re
Read more →Competitive Position
How RFL ranks across every disease it competes inCompetitive Position is a premium feature
See how RFL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial